ARTICLE | Company News
Carbylan Therapeutics neurology news
May 2, 2016 7:00 AM UTC
Carbylan reduced headcount by 14 (82%) to three and suspended development of Hydros-TA. Carbylan is pursuing a strategic transaction, which may include a merger or acquisition of the company. In Febru...